Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S(-)-baclofen is the levorotatory enantiomer of the GABA-B receptor agonist baclofen. While the R(+)-enantiomer (arbaclofen) is the primary active isomer responsible for the therapeutic muscle-relaxant effects of racemic baclofen, S(-)-baclofen is significantly less potent at the GABA-B receptor. Research has identified that S(-)-baclofen may possess distinct pharmacological properties, particularly in the context of sex-dependent responses to alcohol. In preclinical studies, S(-)-baclofen has been shown to increase dopamine release in the nucleus accumbens and, in some female subjects, paradoxically increase alcohol self-administration. It is primarily used as a research tool to investigate the stereospecificity of baclofen's effects and the underlying neurobiology of alcohol use disorder.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S(-)-baclofen.